The infusion from the two pharmaceutical giants brings PathAI’s total Series B funding to $75 million; the startup initially raised $60 million in the round in April. Since its 2016 founding, the Boston-based PathAI has now raised more than $90 million.
The funding will support PathAI’s growing capabilities in clinical development. As David Rubin, PhD, managing director of the Merck innovation fund, explained in a news release, “[PathAI’s] industry-leading work incorporating artificial intelligence into digital pathology holds the potential to change the way we diagnose and treat cancer.”
More articles on AI:
Geisinger, Mayo Clinic, IBM among 25 participants chosen for CMS AI challenge
Patients don’t trust AI — here’s how providers can change that
How Facebook, NYU School of Medicine are using AI to speed MRI readings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
